JP2013524844A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013524844A5 JP2013524844A5 JP2013508489A JP2013508489A JP2013524844A5 JP 2013524844 A5 JP2013524844 A5 JP 2013524844A5 JP 2013508489 A JP2013508489 A JP 2013508489A JP 2013508489 A JP2013508489 A JP 2013508489A JP 2013524844 A5 JP2013524844 A5 JP 2013524844A5
- Authority
- JP
- Japan
- Prior art keywords
- aureus
- protein
- polysaccharide
- recombinant
- gram
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000004676 glycans Chemical class 0.000 claims 32
- 229920001282 polysaccharide Polymers 0.000 claims 32
- 239000005017 polysaccharide Substances 0.000 claims 32
- 108090000623 proteins and genes Proteins 0.000 claims 14
- 102000004169 proteins and genes Human genes 0.000 claims 14
- 108091006036 N-glycosylated proteins Proteins 0.000 claims 13
- 229960005486 vaccine Drugs 0.000 claims 13
- 241000894006 Bacteria Species 0.000 claims 12
- 241000191967 Staphylococcus aureus Species 0.000 claims 8
- 108091035707 Consensus sequence Proteins 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 108700023372 Glycosyltransferases Proteins 0.000 claims 4
- 102000051366 Glycosyltransferases Human genes 0.000 claims 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 4
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 claims 3
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 239000002095 exotoxin Substances 0.000 claims 3
- 231100000776 exotoxin Toxicity 0.000 claims 3
- 229960003085 meticillin Drugs 0.000 claims 3
- 239000000178 monomer Substances 0.000 claims 3
- 108010089072 Dolichyl-diphosphooligosaccharide-protein glycotransferase Proteins 0.000 claims 2
- 101900127397 Staphylococcus aureus Alpha-hemolysin Proteins 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- 101710092462 Alpha-hemolysin Proteins 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 241000192125 Firmicutes Species 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 claims 1
- 150000004043 trisaccharides Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33217010P | 2010-05-06 | 2010-05-06 | |
| US61/332,170 | 2010-05-06 | ||
| PCT/EP2011/057111 WO2011138361A1 (en) | 2010-05-06 | 2011-05-04 | Capsular gram-positive bacteria bioconjugate vaccines |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016197813A Division JP6435583B2 (ja) | 2010-05-06 | 2016-10-06 | 莢膜グラム陽性菌のバイオコンジュゲートワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013524844A JP2013524844A (ja) | 2013-06-20 |
| JP2013524844A5 true JP2013524844A5 (enExample) | 2014-06-26 |
| JP6339366B2 JP6339366B2 (ja) | 2018-06-06 |
Family
ID=44902091
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013508489A Expired - Fee Related JP6339366B2 (ja) | 2010-05-06 | 2011-05-04 | 莢膜グラム陽性菌のバイオコンジュゲートワクチン |
| JP2016197813A Expired - Fee Related JP6435583B2 (ja) | 2010-05-06 | 2016-10-06 | 莢膜グラム陽性菌のバイオコンジュゲートワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016197813A Expired - Fee Related JP6435583B2 (ja) | 2010-05-06 | 2016-10-06 | 莢膜グラム陽性菌のバイオコンジュゲートワクチン |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US8871491B2 (enExample) |
| EP (2) | EP2566507B1 (enExample) |
| JP (2) | JP6339366B2 (enExample) |
| KR (2) | KR20130063510A (enExample) |
| CN (1) | CN103079591B (enExample) |
| AU (2) | AU2011249839B2 (enExample) |
| CA (1) | CA2798381C (enExample) |
| CY (1) | CY1119895T1 (enExample) |
| DK (1) | DK2566507T3 (enExample) |
| ES (2) | ES2844596T3 (enExample) |
| HR (1) | HRP20180064T1 (enExample) |
| HU (1) | HUE037956T2 (enExample) |
| IL (1) | IL222711B (enExample) |
| LT (1) | LT2566507T (enExample) |
| NO (1) | NO2566507T3 (enExample) |
| PL (1) | PL2566507T3 (enExample) |
| PT (1) | PT2566507T (enExample) |
| SG (1) | SG185433A1 (enExample) |
| SI (1) | SI2566507T1 (enExample) |
| WO (1) | WO2011138361A1 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2477794C (en) * | 2002-03-07 | 2013-08-20 | Eidgenoessische Technische Hochschule Zuerich | System and method for the production of recombinant glycosylated proteins in a prokaryotic host |
| HRP20181259T1 (hr) | 2008-02-20 | 2018-10-05 | Glaxosmithkline Biologicals S.A. | Biokonjugati načinjeni iz rekombinantnih n-glikoziliranih proteina iz prokariotskih stanica |
| AU2010322454B2 (en) * | 2009-11-19 | 2016-05-19 | Glaxosmithkline Biologicals S.A. | Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells |
| US9526775B2 (en) | 2012-04-27 | 2016-12-27 | Washington University | Glycoengineered outer membrane vesicles and use thereof as vaccines |
| US9777076B2 (en) | 2012-07-16 | 2017-10-03 | Pfizer Inc. | Saccharides and uses thereof |
| AU2013295647B2 (en) | 2012-07-26 | 2018-02-08 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Multimeric fusion protein vaccine and immunotherapeutic |
| TR201904022T4 (tr) | 2012-10-12 | 2019-04-22 | Glaxosmithkline Biologicals Sa | Konakçı hücre modifikasyon yöntemleri. |
| SG11201503308XA (en) | 2012-11-07 | 2015-05-28 | Glycovaxyn Ag | PRODUCTION OF RECOMBINANT VACCINE IN <i>E. COLI</i> BY ENZYMATIC CONJUGATION |
| CA2923957C (en) | 2013-01-18 | 2021-08-31 | London School Of Hygiene And Tropical Medicine | Glycosylation method |
| GB201301085D0 (en) | 2013-01-22 | 2013-03-06 | London School Hygiene & Tropical Medicine | Glycoconjugate Vaccine |
| US11220676B2 (en) * | 2013-10-11 | 2022-01-11 | Glaxosmithkline Biological Sa | Methods of host cell modification |
| WO2015082571A1 (en) * | 2013-12-04 | 2015-06-11 | Glycovaxyn Ag | Prevention of staphylococcus aureus infections by glycoprotein vaccines synthesized in escherichia coli |
| SI3131577T1 (sl) * | 2014-04-17 | 2020-08-31 | Glaxosmithkline Biologicals S.A. | Modificirane gostiljske celice in uporabe le-teh |
| SG11201700325SA (en) * | 2014-08-08 | 2017-02-27 | Glycovaxyn Ag | Modified host cells and hybrid oligosaccharides for use in bioconjugate production |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| US10500261B2 (en) | 2014-11-05 | 2019-12-10 | The United States Of America As Represented By The Secretary Of The Navy | Synthetic antigen constructs against campylobacter jejuni |
| CA2966754A1 (en) | 2014-11-05 | 2016-05-12 | The United States Of America As Represented By The Secretary Of The Navy | Synthetic antigen constructs against campylobacter jejuni |
| SI3240895T1 (sl) | 2014-12-30 | 2022-04-29 | Glaxosmithkline Biologicals S.A. | Sestavki in postopki za glikozilacijo proteinov |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| BE1024282B1 (fr) * | 2015-07-01 | 2018-01-15 | Glaxosmithkline Biologicals Sa | Compositions immunogènes |
| GB201518668D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
| GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| GB201712678D0 (en) | 2017-08-07 | 2017-09-20 | Glaxosmithkline Biologicals Sa | Process for the manipulation of nucleic acids |
| GB201721582D0 (en) * | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
| GB201721576D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
| CN108330142B (zh) * | 2018-02-09 | 2021-09-17 | 河北科技师范学院 | 一种具有免疫保护作用的美人鱼发光杆菌溶血素Hlych蛋白 |
| GB201802339D0 (en) * | 2018-02-13 | 2018-03-28 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| CN109400704B (zh) * | 2018-11-14 | 2020-07-21 | 珠海泰诺麦博生物技术有限公司 | 一种抗金黄色葡萄球菌α-溶血素的抗体及其应用 |
| WO2020120569A2 (en) | 2018-12-12 | 2020-06-18 | Glaxosmithkline Biologicals Sa | Modified carrier proteins for o-linked glycosylation |
| US12404533B2 (en) | 2019-01-11 | 2025-09-02 | Northwestern University | Bioconjugate vaccines' synthesis in prokaryotic cell lysates |
| EP3757217A1 (en) | 2019-06-27 | 2020-12-30 | GlaxoSmithKline Biologicals S.A. | Methods for protein purification |
| EP3770269A1 (en) | 2019-07-23 | 2021-01-27 | GlaxoSmithKline Biologicals S.A. | Quantification of bioconjugate glycosylation |
| US20220403347A1 (en) | 2019-08-09 | 2022-12-22 | Glaxosmithkline Biologicals S.A. | Mutated pglb oligosaccharyltransferase enzymes |
| EP3777884A1 (en) | 2019-08-15 | 2021-02-17 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| CN112575041B (zh) * | 2019-09-30 | 2022-12-13 | 江南大学 | 一种混合碳源高效发酵生产phb的工程菌及其应用 |
| US20230293657A1 (en) | 2020-06-25 | 2023-09-21 | Glaxosmithkline Biologicals Sa | Vaccine |
| CN114085255B (zh) * | 2020-08-24 | 2023-08-29 | 山东大学 | 一种苏黎世克罗诺杆菌5型脂多糖o-抗原寡糖片段及其制备方法与应用 |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
| US20250270520A1 (en) | 2021-02-11 | 2025-08-28 | Glaxosmithkline Biologicals Sa | Mutated pglb oligosaccharyltransferase enzymes |
| EP4452308A1 (en) | 2021-12-22 | 2024-10-30 | GlaxoSmithKline Biologicals S.A. | Vaccine |
| WO2024002331A1 (en) * | 2022-06-30 | 2024-01-04 | Shanghai Yuguan Biotech Co., Ltd. | A live bacteria strain with reduced capsules |
| GB202302579D0 (en) | 2023-02-23 | 2023-04-12 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| WO2025032534A2 (en) | 2023-08-09 | 2025-02-13 | Glaxosmithkline Biologicals Sa | Modified proteins |
| WO2025032535A2 (en) | 2023-08-09 | 2025-02-13 | Glaxosmithkline Biologicals Sa | Modified proteins |
| CN117771264B (zh) * | 2023-11-27 | 2024-06-25 | 山东省农业科学院畜牧兽医研究所 | circHIF1α在制备抵御细菌感染的新型疫苗中的应用 |
| WO2025172892A1 (en) | 2024-02-16 | 2025-08-21 | Glaxosmithkline Biologicals Sa | Modified proteins and methods |
| CN120005900A (zh) * | 2025-01-21 | 2025-05-16 | 浙江大学 | FaCP5L1和FaCP5L3基因及其在调控果实成熟和采后保鲜品质中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1900A (en) | 1840-12-14 | Machine for extracting stumps | ||
| EP0170204B1 (de) | 1984-08-01 | 1991-09-25 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Neue genetische Sequenzen, die durch sie codierten Interferon-Peptide vom Typ I und diese sie produzierende Organismen |
| US5643758A (en) | 1987-03-10 | 1997-07-01 | New England Biolabs, Inc. | Production and purification of a protein fused to a binding protein |
| EP0726318A1 (en) | 1993-05-14 | 1996-08-14 | The Upjohn Company | An acceptor polypeptide for an N-acetylgalactosaminyltransferase |
| US6503744B1 (en) | 1999-02-01 | 2003-01-07 | National Research Council Of Canada | Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics |
| CA2363297C (en) | 1999-03-02 | 2011-08-09 | Michael J. Betenbaugh | Engineering intracellular sialylation pathways |
| NZ522320A (en) | 2000-05-12 | 2007-03-30 | Neose Technologies Inc | In vitro modification of glycosylation patterns of recombinant glycopeptides |
| EP2267135A3 (en) | 2000-06-30 | 2011-09-14 | Vib Vzw | Protein glycosylation modification in pichia pastoris |
| KR20130101592A (ko) | 2002-03-07 | 2013-09-13 | 아이드게노쉬쉐 테흐니쉐 호흐슐레 쥬리히 | 원핵 숙주에서의 재조합 글리코실화 단백질 생산 방법 및 생산계 |
| CA2477794C (en) | 2002-03-07 | 2013-08-20 | Eidgenoessische Technische Hochschule Zuerich | System and method for the production of recombinant glycosylated proteins in a prokaryotic host |
| CN1671722A (zh) | 2002-08-01 | 2005-09-21 | 加拿大国家研究院 | 弯曲菌的聚糖和糖肽 |
| US8071113B2 (en) | 2004-05-24 | 2011-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Live, oral vaccine for protection against Shigella dysenteriae serotype 1 |
| JP5356807B2 (ja) | 2005-05-11 | 2013-12-04 | アイトヘネーシシェ テフニーシェ ホフシューレ チューリッヒ | 原核細胞由来の組み換えｎ−グリコシル化タンパク質 |
| KR101541383B1 (ko) | 2006-03-30 | 2015-08-03 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 면역원성 조성물 |
| EP2242505A4 (en) * | 2008-01-08 | 2012-03-07 | Biogenerix Ag | GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES |
| HRP20181259T1 (hr) | 2008-02-20 | 2018-10-05 | Glaxosmithkline Biologicals S.A. | Biokonjugati načinjeni iz rekombinantnih n-glikoziliranih proteina iz prokariotskih stanica |
-
2011
- 2011-05-04 ES ES17192866T patent/ES2844596T3/es active Active
- 2011-05-04 ES ES11724567.0T patent/ES2657588T3/es active Active
- 2011-05-04 HU HUE11724567A patent/HUE037956T2/hu unknown
- 2011-05-04 HR HRP20180064TT patent/HRP20180064T1/hr unknown
- 2011-05-04 WO PCT/EP2011/057111 patent/WO2011138361A1/en not_active Ceased
- 2011-05-04 KR KR1020127031847A patent/KR20130063510A/ko not_active Ceased
- 2011-05-04 CA CA2798381A patent/CA2798381C/en active Active
- 2011-05-04 DK DK11724567.0T patent/DK2566507T3/da active
- 2011-05-04 SI SI201131403T patent/SI2566507T1/en unknown
- 2011-05-04 EP EP11724567.0A patent/EP2566507B1/en active Active
- 2011-05-04 JP JP2013508489A patent/JP6339366B2/ja not_active Expired - Fee Related
- 2011-05-04 CN CN201180033560.1A patent/CN103079591B/zh not_active Expired - Fee Related
- 2011-05-04 EP EP17192866.6A patent/EP3281639B1/en active Active
- 2011-05-04 AU AU2011249839A patent/AU2011249839B2/en not_active Ceased
- 2011-05-04 PL PL11724567T patent/PL2566507T3/pl unknown
- 2011-05-04 NO NO11724567A patent/NO2566507T3/no unknown
- 2011-05-04 PT PT117245670T patent/PT2566507T/pt unknown
- 2011-05-04 LT LTEP11724567.0T patent/LT2566507T/lt unknown
- 2011-05-04 US US13/100,603 patent/US8871491B2/en active Active
- 2011-05-04 KR KR1020187004586A patent/KR101916290B1/ko not_active Expired - Fee Related
- 2011-05-04 SG SG2012081535A patent/SG185433A1/en unknown
-
2012
- 2012-10-25 IL IL222711A patent/IL222711B/en active IP Right Grant
-
2014
- 2014-09-23 US US14/494,150 patent/US9585950B2/en not_active Expired - Fee Related
-
2016
- 2016-07-25 AU AU2016208265A patent/AU2016208265A1/en not_active Abandoned
- 2016-10-06 JP JP2016197813A patent/JP6435583B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-25 US US15/414,900 patent/US10307473B2/en active Active
-
2018
- 2018-02-06 CY CY20181100148T patent/CY1119895T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013524844A5 (enExample) | ||
| JP2017036303A5 (enExample) | ||
| Bitrus et al. | Staphylococcus aureus: A review of antimicrobial resistance mechanisms | |
| JP2015214545A5 (enExample) | ||
| NZ591925A (en) | Adjuvant composition comprising a host defense peptide, an immunostimulatory sequence and a polyanionic polymer | |
| SI2566507T1 (en) | Bioconjugate vaccines of capsular Gram-positive bacteria | |
| FI3110441T3 (fi) | Uusi polysakkaridi ja sen käyttöjä | |
| EP4245320A3 (en) | Methods and compositions for immune protection against extra-intestinal pathogenic e. coli | |
| JP2014042533A5 (enExample) | ||
| JP2015533511A5 (enExample) | ||
| JP2016040284A5 (enExample) | ||
| JP2017529849A5 (enExample) | ||
| JP2010284165A5 (enExample) | ||
| JP2011502165A5 (enExample) | ||
| HRP20201021T1 (hr) | Modificirane stanice domaćini i njihova upotreba | |
| JP2010539256A5 (enExample) | ||
| Schroll et al. | Polyamines are essential for virulence in Salmonella enterica serovar Gallinarum despite evolutionary decay of polyamine biosynthesis genes | |
| JP2013531491A5 (enExample) | ||
| Loewen et al. | Genome sequence of a tigecycline-resistant clinical isolate of Acinetobacter baumannii strain AB031 obtained from a bloodstream infection | |
| WO2010115278A8 (en) | Methods and compositions for treating and preventing shiga toxin-producing escherichia coli infection | |
| PH12019500843A1 (en) | Vaccine contructs and uses thereof against staphylococcus infections | |
| JP2013512675A5 (enExample) | ||
| JP2017537941A5 (enExample) | ||
| WO2018147265A1 (ja) | 病原性グラム陰性菌に対するワクチン | |
| EP4110793A1 (en) | Genetically engineered microorganisms that overexpress microcin-mge and methods of purification and use |